期刊文献+
共找到15篇文章
< 1 >
每页显示 20 50 100
Testicular Burkitt’s Lymphoma: A Case Report and Literature Review
1
作者 Junior Bathelemy Mekeme Mekeme Jean Cedrick Fouda +12 位作者 Philip Fernandez Owono Abessolo Axel Nwaha Makon Marcella Delboise Biyouma Georges Kemegni Atenguena Christian Awoundja Marcel Junior Mekeme Yon Ngapagna Paul Adrien Atangana Pierre Ongolo Zogo Etoundi Paul Owono Pierre Joseph Fouda Angwafo III Fru 《Open Journal of Urology》 2023年第9期327-336,共10页
Background: Burkitt’s lymphoma of the testis (TBL) is a rare and extremely aggressive malignant usually diagnosed in front of a testicular mass. We describe an interesting single case of TBL managed by a combined mul... Background: Burkitt’s lymphoma of the testis (TBL) is a rare and extremely aggressive malignant usually diagnosed in front of a testicular mass. We describe an interesting single case of TBL managed by a combined multimodal approach with a review of the literature. Case Report: A patient aged 69-year-old male, newly hypertensive, who presented with a twelve-month history of right testis progressive painful scrotal swelling, which worsens following a motorbike accident. Clinical examination revealed a large tender mass in an erythematous right scrotal bursa. A scrotal ultrasound showed a right heterogenous intra-testicular mass. The patient underwent unilateral (right) radical orchiectomy. Histopathological examination revealed presence of monomorphic lymphoid cells, with moderate to increased size, dissociated inconstantly by macrophages consistent with a Burkitt’s-like non-Hodgkin Lymphoma. After surgery, the patient was transferred to oncologist for adjuvant chemotherapy. Conclusion: A testicular mass is a usual circumstance for the discovery of a primary tumour of the testicle. Burkitt’s testicular lymphoma is a rare tumour whose diagnosis is based on histological findings. There are non-consensual etiological or predisposing factors. The treatment depends imperatively on the stage of the disease. Therapeutic modalities relay on in surgical excision, chemotherapy and radiation therapy but the accurate procedures are not standardized. 展开更多
关键词 burkitts lymphoma ORCHIDECTOMY TEsTIs
下载PDF
Gallbladder Burkitt's lymphoma mimicking gallbladder cancer:A case report
2
作者 Kiyotaka Hosoda Akira Shimizu +12 位作者 Koji Kubota Tsuyoshi Notake Hikaru Hayashi Koya Yasukawa Kentaro Umemura Atsushi Kamachi Takamune Goto Hidenori Tomida Shiori Yamazaki Yuri Narusawa Naoko Asano Takeshi Uehara Yuji Soejima 《World Journal of Gastroenterology》 SCIE CAS 2022年第6期675-682,共8页
BACKGROUND Malignant lymphoma is a rare form of gallbladder malignancy.Most of these malignancies are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type lymphomas;however,Burkitt’s lymphoma of t... BACKGROUND Malignant lymphoma is a rare form of gallbladder malignancy.Most of these malignancies are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type lymphomas;however,Burkitt’s lymphoma of the gallbladder is extremely rare,and only two previous reports are available in the literature.Herein,we report a rare case of Burkitt’s lymphoma of the gallbladder mimicking gallbladder adenocarcinoma.CASE SUMMARY An 83-year-old man with no abdominal complaints was found to have a gallbladder tumor and periportal lymph node enlargement on computed tomography(CT)performed for hypertension screening.His laboratory data revealed slightly elevated serum levels of carcinoembryonic antigen and soluble interleukin 2 receptor.Imaging examinations revealed two irregular and contrastenhanced masses extending into the gallbladder lumen,but these did not infiltrate the serosa.Moreover,a periportal lymph node had enlarged to 30 mm.Based on these findings,we diagnosed the patient as having gallbladder adenocarcinoma with lymph node metastasis,which was treated using bile duct resection with gallbladder bed resection and periportal lymph node dissection.However,the patient was finally diagnosed as having Burkitt’s lymphoma.Although the surgical margin was pathologically negative,recurrence was noted at the hepatic radical margin and superior pancreaticoduodenal lymph nodes on positron emission tomography/CT soon after discharge.Thus,he was referred to a hematologist and started receiving treatment with reduced-dose cyclophosphamide,doxorubicin,vincristine,and prednisone.CONCLUSION Burkitt’s lymphoma can occur in the gallbladder.Biopsy can be useful in cases with findings suggestive of gallbladder malignant lymphoma. 展开更多
关键词 GALLBLADDER Malignant lymphoma burkitts lymphoma Gallbladder cancer LYMPHADENOPATHY Case report
下载PDF
长春新碱传递体对荷Burkitt’s淋巴瘤裸鼠的抑瘤活性评价 被引量:7
3
作者 卢懿 侯世祥 +3 位作者 李晔 张良珂 沈富兵 鞠青 《中国药学杂志》 CAS CSCD 北大核心 2008年第12期910-913,共4页
目的评价长春新碱传递体(vincristine loaded transfersom es,VCR-T)对荷Burk itt’s淋巴瘤裸鼠的抑瘤效果。方法建立荷Burk itt’s淋巴瘤的裸鼠模型,将VCR-T分为高(0.8 mg.kg-1)、中(0.2 mg.kg-1)、低(0.05 mg.kg-1)剂量以及单次给药和... 目的评价长春新碱传递体(vincristine loaded transfersom es,VCR-T)对荷Burk itt’s淋巴瘤裸鼠的抑瘤效果。方法建立荷Burk itt’s淋巴瘤的裸鼠模型,将VCR-T分为高(0.8 mg.kg-1)、中(0.2 mg.kg-1)、低(0.05 mg.kg-1)剂量以及单次给药和3次给药组,长春新碱溶液(vincristine solution,VCR-Sol)以0.8 mg.kg-1的剂量分3次静脉注射,比较各组荷瘤裸鼠的相对肿瘤增殖率、肿瘤生长曲线、抑瘤率,并进行瘤体组织学检查考察VCR-T的抑瘤效果。结果各治疗组对肿瘤的生长均有一定的抑制作用,且随着给药剂量及给药次数的增加,对肿瘤的抑制作用也相应的增加;VCR-T以0.8 mg.kg-1剂量单次给药则可达到与VCR-Sol相同的效果,而0.2 mg.kg-1剂量3次给药的疗效则优于VCR-Sol;所有VCR-T组裸鼠100%存活,VCR-Sol组裸鼠存活率仅75%。结论VCR-T透皮给药具有比VCR-Sol静注给药更好的抑瘤效果。 展开更多
关键词 长春新碱传递体 burkitts淋巴瘤 透皮 药效学
下载PDF
hsa-miR-150再表达对Burkitt淋巴瘤增殖与凋亡的影响
4
作者 陈少红 韩西群 +3 位作者 代新珍 简文静 严金海 赵彤 《临床与实验病理学杂志》 CAS CSCD 北大核心 2014年第8期829-834,共6页
目的探讨hsa-miR-150在正常人B淋巴细胞群及人Burkitt淋巴瘤(Burkitt’s lymphoma,BL)中的表达,分析hsa-miR-150再表达对人BL细胞株Daudi及Raji体外增殖及凋亡的影响。方法采用流式细胞技术(flow cytometry,FCM)从扁桃体炎标本中分选出... 目的探讨hsa-miR-150在正常人B淋巴细胞群及人Burkitt淋巴瘤(Burkitt’s lymphoma,BL)中的表达,分析hsa-miR-150再表达对人BL细胞株Daudi及Raji体外增殖及凋亡的影响。方法采用流式细胞技术(flow cytometry,FCM)从扁桃体炎标本中分选出正常B淋巴细胞群,应用qRT-PCR技术检测hsa-miR-150在细胞群中的表达,同时检测hsa-miR-150在BL细胞株Daudi及Raji中的表达;将载有hsa-miR-150的慢病毒稳定转染Daudi及Raji,采用FCM、MTT及IP染色法观察hsa-miR-150再表达对Daudi及Raji细胞增殖与凋亡的影响。结果 FCM从扁桃体组织中分选出4群正常的B淋巴细胞群,分别为nave细胞(NC)、中心母细胞(CB)、中心细胞(CC)、记忆B细胞(MC),hsa-miR-150在NC、CB、CC、MC中的表达呈动态性,相对于NC,CB及CC低表达hsa-miR-150(P<0.001)。与正常B淋巴细胞相比,hsa-miR-150在Daudi及Raji中明显低表达(P<0.001)。与对照组相比,实验组细胞增殖明显受抑制(P<0.001),凋亡明显增加(P<0.001)。结论 hsa-miR-150对正常B淋巴细胞的分化具有重要作用,与BL的发生、发展可能存在一定关系;hsa-miR-150再表达可抑制Daudi及Raji细胞增殖,诱导其凋亡,为后续诱导分化治疗研究打下基础。 展开更多
关键词 burkitt淋巴瘤 hsa-miR-150 Daudi细胞株 RAJI细胞株 增殖 凋亡
下载PDF
Burkitt淋巴瘤11例临床病理分析 被引量:7
5
作者 胡丹 陈刚 +1 位作者 郑雄伟 力超 《诊断病理学杂志》 CSCD 2009年第4期251-254,共4页
目的探讨Burkitt淋巴瘤(BL)的临床病理特征、诊断和鉴别诊断。方法收集11例BL和10例弥漫大B细胞淋巴瘤(DLBCL),采用免疫组化EnVision二步法检测肿瘤细胞免疫表型,标记抗体为CD20、PAX-5、CD3、CD7、CD10、bcl-2、bcl-6、MUM-1、Ki-... 目的探讨Burkitt淋巴瘤(BL)的临床病理特征、诊断和鉴别诊断。方法收集11例BL和10例弥漫大B细胞淋巴瘤(DLBCL),采用免疫组化EnVision二步法检测肿瘤细胞免疫表型,标记抗体为CD20、PAX-5、CD3、CD7、CD10、bcl-2、bcl-6、MUM-1、Ki-67;采用EBER原位杂交方法检测肿瘤细胞的EBV感染情况。结果根据细胞形态BL分为3种类型:经典型8例,浆样分化型1例,非典型性BL/BL样型2例。BL和DLBCL的所有病例CD20和PAX-5(+)。BL中bcl-2和MUM-1的表达率明显低于DLBCL(P〈0.01),而同时表达CD10(+)/bcl-2(-)/bcl-6(+)和Ki-67≥95%的病例明显多于DLBCL(P〈0.01)。结论BL是一种高度恶性的B细胞淋巴瘤,免疫组化在BL的诊断及鉴别诊断中有重要作用。BL的倍增时间短,宜采取短疗程、高强度化疗方案。 展开更多
关键词 burkitt淋巴瘤 诊断 鉴别诊断 免疫组化
下载PDF
Regulatory Effects of Deguelin on Proliferation and Cell Cycle of Raji Cells 被引量:1
6
作者 熊金蓉 刘红利 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2013年第4期491-495,共5页
Summary: The underlying mechanism of deguelin regulating the cell cycle in human Burkitt's lym phoma cell line Raji cells in vitro, and the cytotoxicity of deguelin to Raji cells and human peripheral blood monocular... Summary: The underlying mechanism of deguelin regulating the cell cycle in human Burkitt's lym phoma cell line Raji cells in vitro, and the cytotoxicity of deguelin to Raji cells and human peripheral blood monocular cells (PBMCs) were investigated. The effects of deguelin on the growth of Raji cells were studied by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium (MTT) assay. Apoptosis was detected through Hoechst 33258 staining. The effect of deguelin on the cell cycle of Raji cells was studied by a propidium iodide method. The expression levels of cyclin D1, P21 and pRb were examined by using Western blotting. The results showed that the proliferation of Raji cells was inhibited in the de guelin-treated group, with a 24-h IC5o value of 21.61 nmol/L and a 36-h IC50 value of 17.07 nmol/L. Proliferation in Raji cells was inhibited significantly by deguelin, while little change was observed in PBMCs. Deguelin induced G2/M arrest in Raji cells. The expression of cyclin D1, P21 and pRb was dramatically down-regulated by deguelin in a dose-dependent manner. It was concluded that deguelin could inhibit the proliferation of Raji cells by arresting the cells at GE/M phase and inducing the cell apoptosis. Moreover, deguelin selectively induced apoptosis of Raji cells with low toxicity to PBMCs. The antitumor effects of deguelin were related to the down-regulated expression of cyclin D1, P21 and pRb proteins. 展开更多
关键词 DEGUELIN cell cycle apoptosis burkitts lymphoma
下载PDF
Trichostatin A Regulates hGCN5 Expression and Cell Cycle on Daudi Cells in vitro
7
作者 刘红利 陈燕 +3 位作者 崔国惠 伍钢 王涛 胡健莉 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2006年第5期534-537,共4页
The expression of human general control of amino acid synthesis protein 5 (hGCN5) in human Burkitt's lymphoma Daudi cells in vitro, effects of Trichostatin A (TSA) on cell proliferation and apoptosis and the mole... The expression of human general control of amino acid synthesis protein 5 (hGCN5) in human Burkitt's lymphoma Daudi cells in vitro, effects of Trichostatin A (TSA) on cell proliferation and apoptosis and the molecular mechanism of TSA inhibiting proliferation of Daudi cells were investigated. The effects of TSA on the growth of Daudi cells were studied by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium (MTT) assay. The effect of TSA on the cell cycle of Daudi cells was assayed by a propidium iodide method. Immunochemistry and Western blot were used to detect the expression of hGCN5. The proliferation of Daudi cells was decreased in TSA-treated group with a 24 h IC50 value of 415.3979 μg/L. TSA induced apoptosis of Daudi cells in a timeand dose-dependent manner. Treatment with TSA (200 and 400 μg/L) for 24 h, the apoptosis rates of Daudi cells were (14.74±2.04) % and (17.63±1.25) %, respectively. The cell cycle was arrested in G0/G1 phase (50, 100 μg/L) and in G2/M phase (200 μg/L) by treatment with TSA for 24 h. The expression of hGCN5 protein in Daudi cells was increased in 24 h TSA-treated group by immunochemistry and Western blot (P〈0.05). It was suggested that TSA as HDACIs could increase the expression of hGCN5 in Daudi cells, and might play an important role in regulating the proliferation and apoptosis of B-NHL cell line Daudi cells. 展开更多
关键词 Trichostatin A hGCN5 burkitts lymphoma DAUDI
下载PDF
One Month Ongoing Intussusception: Case Report
8
作者 Emrah Aydin 《Open Journal of Pediatrics》 2016年第1期14-16,共3页
The aim is to present a case operated due to one-month ongoing intussusception and diagnosed as lymphoma. A six years old boy was admitted to our emergency department with complaint of colicky abdominal pain and bilio... The aim is to present a case operated due to one-month ongoing intussusception and diagnosed as lymphoma. A six years old boy was admitted to our emergency department with complaint of colicky abdominal pain and bilious vomiting for the last month. He was operated due to 3 cm intussusception at ileocecal part. A mass which is about 6 cm in diameter, hard, partly mobile and invaginate the intestine at its posterior aspect was found. Pathology was reported as Burkitt lymphoma. He received two cycles of chemotherapy at post-operative period. He is still event free for the last two years. One must remember that lymphoma can be the lead point in intussusception especially in elderly children. 展开更多
关键词 INTUssUsCEPTION burkitts lymphoma CHILDHOOD
下载PDF
Reversible Posterior Leukoencephalopathy Syndrome Sometimes Could be Irreversible: A Case Following Tumor Lysis Syndrome in Childhood Burkitt's Lymphoma
9
作者 Rui Zhang Ling Jin +4 位作者 Hua Cheng Jing Yang Yan-Long Duan Shuang Huang Yong-Hong Zhang 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第4期480-483,共4页
Reversible posterior leukoencepbalopathy syndrome (RPLS) was first described by Hinchey eta/. in 1996 as a clinical radiologic syndrome consisting of reversible cortical neuroIogic dysIhnction and brain imaging find... Reversible posterior leukoencepbalopathy syndrome (RPLS) was first described by Hinchey eta/. in 1996 as a clinical radiologic syndrome consisting of reversible cortical neuroIogic dysIhnction and brain imaging findings involving the posterior circulation, especially the occipital lobes. 展开更多
关键词 burkitts lymphoma CHILDHOOD Reversible Posterior Leukoencephalopathy syndrome Tumor Lysis syndrome
原文传递
EB病毒感染相关的儿童散发性伯基特淋巴瘤中miR-127和miR-155表达及意义 被引量:9
10
作者 林云 杨文萍 +5 位作者 黄慧 徐红艳 吴艳 曾松涛 熊枫 肖强 《临床与实验病理学杂志》 CAS CSCD 北大核心 2013年第10期1076-1080,共5页
目的探讨miR-127、miR-155在EB病毒(epstein-barr virus,EBV)阳性/阴性的儿童散发性伯基特淋巴瘤(Burkitt’s lymphoma,BL)中的表达。方法采用原位杂交和qRT-PCR技术检测40例儿童BL及15例扁桃体组织2株细胞株(Raji和Ramos)的EBER及miR-... 目的探讨miR-127、miR-155在EB病毒(epstein-barr virus,EBV)阳性/阴性的儿童散发性伯基特淋巴瘤(Burkitt’s lymphoma,BL)中的表达。方法采用原位杂交和qRT-PCR技术检测40例儿童BL及15例扁桃体组织2株细胞株(Raji和Ramos)的EBER及miR-127、miR-155表达情况。结果 (1)40例BL儿童中16例EBER阳性,15例扁桃体EBER均阴性。(2)miR-127在EBV阳性的BL中的表达(2.68±2.95)比EBV阴性的BL(0.36±0.24)及扁桃体组织(1.23±4.09)高,差异有显著性(P<0.05);Raji和Ramos比较,miR-127表达显著升高(t=-13.038,P=0.000)。(3)miR-155在EBV阳性BL(22.50±56.84)和阴性BL(15.89±51.57)中表达差异无显著性(P>0.05);与扁桃体组织相比表达(0.31±0.54)上调(P<0.05);Raji和Ramos比较,miR-155表达显著升高(t=-3.337,P=0.008)。结论 miR-127和miR-155的高表达与儿童BL的发病机制密切相关,miR-127高表达与EBV感染相关,可能起着类似癌基因的作用。 展开更多
关键词 伯基特淋巴瘤 EB病毒 微小RNA
下载PDF
荧光原位杂交法检测成熟B淋巴肿瘤细胞c-myc断裂 被引量:3
11
作者 王坚敏 汤静燕 +6 位作者 沈立松 顾龙君 潘慈 陈静 宋得莲 蒋黎敏 李莉 《中国小儿血液与肿瘤杂志》 CAS 2008年第2期49-52,共4页
目的建立荧光原位杂交(FISH)方法检测8号染色体c-myc基因断裂,为临床筛选Burkitt’s淋巴瘤和成熟B型淋巴细胞白血病(B-ALL)提供方法。方法11例临床标本,FISH检测5例阴性,6例阳性。结果期待阴性的5例标本全部阴性,期待阳性的6例标本4例... 目的建立荧光原位杂交(FISH)方法检测8号染色体c-myc基因断裂,为临床筛选Burkitt’s淋巴瘤和成熟B型淋巴细胞白血病(B-ALL)提供方法。方法11例临床标本,FISH检测5例阴性,6例阳性。结果期待阴性的5例标本全部阴性,期待阳性的6例标本4例呈现阳性。结论用FISH法检测Burkitt’s淋巴瘤/B-ALL相关的myc基因断裂可行并基本可靠。 展开更多
关键词 荧光原位杂交 burkitts 淋巴瘤 白血病 淋巴细胞 B型
下载PDF
巴布亚新几内亚头颈部恶性淋巴瘤90例回顾性研究
12
作者 李明 《激光杂志》 CAS CSCD 北大核心 2013年第5期114-115,共2页
目的:研究10年期间(1996至2005),年龄18岁以上,90例成人巴布亚新几内亚头颈部恶性淋巴瘤的临床发病率及治疗资料。方法临床资料的获得是从莫尔比滋港总院的医学记录,相关的治疗方法和随访资料是从巴布亚新几内亚国家癌症中心,及Angau Me... 目的:研究10年期间(1996至2005),年龄18岁以上,90例成人巴布亚新几内亚头颈部恶性淋巴瘤的临床发病率及治疗资料。方法临床资料的获得是从莫尔比滋港总院的医学记录,相关的治疗方法和随访资料是从巴布亚新几内亚国家癌症中心,及Angau Memorial Hospital,Lae获得。结果:10年期间总的300例成人恶性淋巴瘤中,头颈部区域90例,非霍奇金氏淋巴瘤72例,其中包括8例成人Burkitts-like lymphoma,18例霍奇金氏淋巴瘤。结论在巴布亚新几内亚,恶性淋巴瘤原发在头颈区域的占总的淋巴瘤的30%。占头颈部所有恶性肿瘤的2.8%。这些淋巴瘤在这些区域表现更强的侵袭性,确切的组织病理学诊断和联合放化疗是治疗的关键因素。 展开更多
关键词 burkitts lymphoma 化疗 头颈部恶性淋巴瘤 非霍奇金氏淋巴瘤 霍奇金氏淋巴瘤 副鼻窦 唾液腺
下载PDF
伯基特淋巴瘤与EB病毒的关系及其p53和bcl-2蛋白的表达 被引量:15
13
作者 李佩娟 崔全才 +3 位作者 王志永 何乐健 刘淑荣 刘彤华 《中华病理学杂志》 CAS CSCD 北大核心 1998年第4期258-261,共4页
目的了解伯基特淋巴瘤和EB病毒的关系及p53和bcl2蛋白的表达。方法采用PCR、原位PCR及免疫组化LSAB方法,检测了28例伯基特淋巴瘤石蜡包埋的组织块。结果发现8例EB病毒DNA阳性,阳性率为28.5%,8例... 目的了解伯基特淋巴瘤和EB病毒的关系及p53和bcl2蛋白的表达。方法采用PCR、原位PCR及免疫组化LSAB方法,检测了28例伯基特淋巴瘤石蜡包埋的组织块。结果发现8例EB病毒DNA阳性,阳性率为28.5%,8例阳性病例做了原位杂交,其中3例为阳性。27例做了p53和bcl2免疫组化检测,阳性病例各为12例(44.4%)和13例(48.1%)。Ⅰ~Ⅱ期和Ⅲ~Ⅳ期p53和bcl2阳性病例分别为3例(230%)、9例(64.2%)和3例(230%)、10例(71.4%),两者均表现Ⅲ~Ⅳ期阳性率高于Ⅰ~Ⅱ期。χ2检验:P<005,差异有显著性。EB病毒、p53和bcl2同时阳性的有4例,EB病毒和p53同时阳性的有5例,EB病毒和bcl2同时阳性的有4例,p53和bcl2同时阳性的(包括EB病毒、p53和bcl2同时阳性的病例在内)共有9例,即EB病毒阳性的病例有半数以上合并p53和bcl2阳性,而p53和bcl2则有70%左右阳性病例同时有阳性表达。结论肿瘤内EB病毒DNA阳性率和非洲型伯基特淋巴瘤不同,而和世界各地报道的散发型相似;肿瘤内p53和bcl2表达Ⅲ~Ⅳ期明显高于Ⅰ~Ⅱ? 展开更多
关键词 伯基特淋巴瘤 疱疹病毒 P53蛋白 BCL-2 淋巴瘤
原文传递
利妥昔单抗联合改良NHL-BFM-90方案对儿童及青少年伯基特淋巴瘤的远期疗效 被引量:9
14
作者 李永新 尹青松 +5 位作者 艾昊 米瑞华 张丽娜 李玉富 魏旭东 宋永平 《中华医学杂志》 CAS CSCD 北大核心 2019年第8期605-610,共6页
目的评估利妥昔单抗联合改良NHL-BFM-90方案对儿童和青少年伯基特淋巴瘤(BL)的远期疗效。方法回顾性分析病理确诊的67例接受改良NHL-BFM-90方案±利妥昔单抗治疗的初治儿童和青少年BL患者的临床特征与疗效。结果64例BL患者(95.52%)... 目的评估利妥昔单抗联合改良NHL-BFM-90方案对儿童和青少年伯基特淋巴瘤(BL)的远期疗效。方法回顾性分析病理确诊的67例接受改良NHL-BFM-90方案±利妥昔单抗治疗的初治儿童和青少年BL患者的临床特征与疗效。结果64例BL患者(95.52%)获完全缓解(CR),3例(4.48%)获部分缓解(PR),总有效率(CR+PR)为100%。中位随访44(3~89)个月,3年和5年总生存(OS)率分别为92.54%和88.98%,3年和5年无进展生存(PFS)率均为90.34%。低危、中危和高危组患者的5年OS率分别为100%、91.7%和80.0%,差异有统计学意义(P=0.048)。55例(82.09%)联合利妥昔单抗治疗,与单纯化疗组的5年OS和PFS分别为74.3%和78.6%相比,利妥昔单抗联合化疗组BL患者的5年OS和PFS分别为95.2%和95.5%,显示出明显生存优势(P值分别为0.021和0.036)。主要不良反应为骨髓抑制和黏膜炎,无治疗相关死亡。结论利妥昔单抗联合改良NHL-BFM-90方案对儿童和青少年BL疗效显著,明显改善患者的长期生存率。 展开更多
关键词 伯基特淋巴瘤 利妥昔单抗 青少年 长期生存
原文传递
5-氮杂-2’-脱氧胞苷对伯基特淋巴瘤NAMALWA细胞株增殖及阳性调控区锌指蛋白1α基因表达的影响 被引量:1
15
作者 刘林 张凤 《白血病.淋巴瘤》 CAS 2012年第10期607-610,共4页
目的探讨DNA甲基化抑制剂5.氮杂-2’-脱氧胞苷(5-Aza-CdR)对伯基特淋巴瘤NAMALWA细胞株增殖及抑癌基因阳性调控区锌指蛋白10[(PRDM101)表达的影响。方法四甲基偶氮唑蓝(MTr)法检测5-Aza.CdR对NAMALWA细胞株增殖的影响,SYBRGree... 目的探讨DNA甲基化抑制剂5.氮杂-2’-脱氧胞苷(5-Aza-CdR)对伯基特淋巴瘤NAMALWA细胞株增殖及抑癌基因阳性调控区锌指蛋白10[(PRDM101)表达的影响。方法四甲基偶氮唑蓝(MTr)法检测5-Aza.CdR对NAMALWA细胞株增殖的影响,SYBRGreen相对定量反转录聚合酶链反应方法检测PRDM10α基因表达水平。结果5-Aza.CdR可抑制NAMALWA细胞的增殖,且表现为浓度依赖性,在终浓度为0.01、0.0625、0.1、0.125、0.25、0.5、1、2和4μmol/L时对NAMALWA细胞株的抑制率分别为21.93%、39.23%、47.69%、50.37%、53.54%、57.72%、62_31%、65.68%和67.87%,且不同药物浓度间吸光度值比较,差异有统计学意义(均P〈0.01)。同时,5-Aza—CdR能使NAMALWA细胞株中PRDM1α重新表达,0.5、1、2μmol/L加药组与对照组比较,△Cf之间差异有统计学意义(P〈0.05)。结论DNA甲基化抑制剂5-Aza—CdR能显著抑制伯基特淋巴瘤NAMALWA细胞株增殖,可能与其诱导的PRDM1α基因的去甲基化和PRDM1α的再表达有关。 展开更多
关键词 DNA甲基化抑制剂 伯基特淋巴瘤 NAMALWA细胞株 阳性调控区锌指蛋白 1α基因 细胞增殖
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部